No interest in this stock as yet.It seems very poorly...

First 3 Last

Share
Profile

Follow
Lefevre

10,123 Posts.

1041

02/08/22

15:45

Post #: 62880308
Share

Originally posted by triage: ↑

I am going to repost these words by Lefevre from 30 June as a reminder of this company's short to medium term focus:

"I believe that Genova has 15000 clinicians. I remember Luke mentioning in a podcast that he is expecting at least 1 Microba kit sale per month per clinician which at A$90 per kit is $1,350,000 per month.

Geneva expects big things which is why they have invested in their own lab. They will promote to their 15000 clinicians and expect results. Once the lab is done with their work the data is sent to Microba in Brisbane for the IP protected algo to do its thing. It's about 90% profit margin to Microba.

It will probably take 6 months or so for Geneva to start reaching targets.

It's a brilliant model. Huge growth ahead.

I expect in years time we will be on a $20 mil plus run rate."

Luke Reid, their CEO, has said that a feature that makes Microba very different from its seeming peers that are all working through the clinical studies process is that Microba is not years away from revenue like the rest of them are. Microba already gets revenue from its kits and if the figures that Lefevre used are even close to the mark then by the end of this fiscal year its revenue will be multiples of what it is now. Definitely something to work with there imo.

Expand

No interest in this stock as yet.
It seems very poorly misunderstood by the market.

There was a circa 5 million share crossing at just under 30 cents yesterday. Interesting.
Looks like you can only trade by appointment.

MAP Price at posting: 27.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

EMD

Emyria Advances kicks off National Rollout with Avive Health Agreement

BEO

One of the biggest jumps today is the most obscure: Beonic Ltd up +65%

HotCopper Trends: Vection's $7M, Liontown dips & Wildcat PFS

ASX Market Close: Index treads water as Energy stocks lead

WC8

Wildcat’s PFS elicits lacklustre response

First 3 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 9.2¢		Change -0.004(4.17%)		Mkt cap ! $47.38M

Open	High	Low	Value	Volume
9.6¢	9.6¢	9.2¢	$11.09K	118.8K

Buyers (Bids)

No.	Vol.	Price($)
5	20774	9.2¢

Sellers (Offers)

Price($)	Vol.	No.
9.5¢	114482	1

View Market Depth

No.	Vol.	Price($)
5	20774	0.092
4	60967	0.091
7	405677	0.090
2	192844	0.089
2	12552	0.088

Price($)	Vol.	No.
0.095	114482	1
0.099	88000	1
0.100	100000	1
0.105	103000	1
0.110	1714	1

Last trade - 15.11pm 29/07/2025 (20 minute delay)

MAP (ASX) Chart

No interest in this stock as yet.It seems very poorly...

Emyria Advances kicks off National Rollout with Avive Health Agreement

One of the biggest jumps today is the most obscure: Beonic Ltd up +65%

HotCopper Trends: Vection's $7M, Liontown dips & Wildcat PFS

ASX Market Close: Index treads water as Energy stocks lead

Wildcat’s PFS elicits lacklustre response

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

No interest in this stock as yet.It seems very poorly...

Top Stories

Emyria Advances kicks off National Rollout with Avive Health Agreement

One of the biggest jumps today is the most obscure: Beonic Ltd up +65%

HotCopper Trends: Vection's $7M, Liontown dips & Wildcat PFS

ASX Market Close: Index treads water as Energy stocks lead

Wildcat’s PFS elicits lacklustre response

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News